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Polyelectrolyte complex micelles were prepared by self-assembly of polypeptide-based tri-
block copolymer as a new drug carrier for cancer chemotherapy. The triblock copolymer,
poly(L-aspartic acid)-b-poly(ethylene glycol)-b-poly(L-aspartic acid) (PLD-b-PEG-b-PLD),
spontaneously self-assembled with doxorubicin (DOX) via electrostatic interactions to form
spherical micelles with a particle size of 60e80 nm (triblock ionomer complexes micelles,
TBIC micelles). These micelles exhibited a high loading capacity of 70% (w/w) at a drug/
polymer ratio of 0.5 at pH 7.0. They showed pH-responsive release patterns, with higher
release at acidic pH than at physiological pH. Furthermore, DOX-loaded TBIC micelles
exerted less cytotoxicity than free DOX in the A-549 human lung cancer cell line. Confocal
microscopy in A-549 cells indicated that DOX-loaded TBIC micelles were transported into
lysosomes via endocytosis. These micelles possessed favorable pharmacokinetic charac-
teristics and showed sustainedDOX release in rats. Overall, these findings indicate that PLD-
b-PEG-b-PLD polypeptide micelles are a promising approach for anti-cancer drug delivery.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Doxorubicin (DOX) is a widely used chemotherapeutic agent
that is highly effective against a range of tumors, including; fax: þ82 53 810 4654.




University. Production anbreast, ovarian, lung, and thyroid cancer. However, its thera-
peutic effects have been limited by its poor pharmacokinetic
profile and its severe adverse effects, including cardiomyop-
athy and congestive heart failure [1e4]. Thus, a smart drug
delivery system is needed to maximize the therapeuticJ.O. Kim).
sity
d hosting by Elsevier B.V. All rights reserved.
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tumor delivery [1,3].
Although a wide range of drug delivery systems is avail-
able, polymer-based drug delivery systems have attracted
attention owing to their small size and their ability to contain
a wide range of therapeutic agents [5]. Nanoscale polymeric
micelles have several beneficial features, including long blood
circulation times, avoidance of renal excretion, and passive
targeting via the enhanced permeability and retention effect
(EPR effect) [6,7].
Recently, nanofabrication of polymeric micelles has been
considerably advanced by the use of block copolymers con-
taining ionic and nonionic blocks (“block ionomers”) [8,9].
Such block copolymers react with oppositely charged species
through electrostatic interaction, resulting in block ionomer
complexes (BIC). Neutralization of ionic chains leads to the
formation of hydrophobic segments, which facilitate genera-
tion of nano-sized particles. Furthermore, BIC possess a cor-
eeshell architecture, with the drug incorporated in a
hydrophobic core palisaded by hydrophilic and nonionic
chains, generally poly(ethylene glycol) (PEG) [10,11]. The PEG
corona prevents nanoparticles from being captured by retic-
uloendothelial systems (RES) and from aggregation, ensuring
their in vivo longevity [12e14]. The small size of the BIC mi-
celles leads to extravasation, enabling penetration into tissues
and cells. BIC micelles have been intensively investigated
because of their ability to carry low-molecular-weight drugs
[15], proteins [16,17], genes [18], and imaging agents [19e21]. In
particular, polypeptide-based block ionomers have been
extensively explored as effective drug delivery systems for
anti-cancer drugs, owing to their biocompatibility, biode-
gradability, and lack of toxicity [22e25].
Various polypeptide-based polymers have been synthe-
sized and investigated in recent years [21,26e28]. However,
the majority of studies have been of diblock copolymers and
there have been fewer investigations of triblock copolymers.
The present study therefore explored the polypeptide-based
triblock copolymer, poly(L-aspartic acid)-b-poly(ethylene gly-
col)-b-poly(L-aspartic acid) (PLD-b-PEG-b-PLD), to develop a
biodegradable nanocarrier for the delivery of anti-cancer
drugs. We prepared triblock ionomer complex micelles (TBIC
micelles) and evaluated their physicochemical properties, as
well as their DOX-loading efficiencies and in vitro release be-
haviors in different pH environments. We also investigated
the cytotoxicity of DOX delivered using TBIC micelles and the
pharmacokinetics of DOX-containing TBIC micelles in an
in vivo animal model.2. Materials and methods
2.1. Materials
Poly(L-aspartic acid)-b-poly(ethylene glycol)-b-poly(L-aspartic
acid) (PLD-b-PEG-b-PLD) triblock copolymers (Mw/Mn ¼ 1.20,
Mw ¼ 7700) were purchased from Alamanda Polymers, Inc.
(Huntsville, AL, USA). The block lengths were 114 and 10
repeating units for PEG and PLD, respectively. DoxorubicinHCl
(DOX) was kindly provided by Dong-A Pharmaceutical Com-
pany (Yongin, Korea). A-549 cells were obtained from theKorean Cell Line Bank (Seoul, Korea). MTT reagent (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and
paraformaldehyde were purchased from SigmaeAldrich (St
Louis, MO, USA). Lysotracker® green and dimethyl sulfoxide
(DMSO) solution were obtained from Invitrogen Inc. (Carlsbad,
CA, USA) and Applichem (Darmstadt, Germany), respectively.
RPMI 1640, penicillin and streptomycin, and heat-inactivated
fetal bovine serum (FBS) were supplied by Hyclone (Logan,
UT, USA). All other reagents were of analytical grade and used
without further purification.2.2. Preparation of polyelectrolyte complex micelles
TBIC micelles were prepared by polyion complexation of the
anionic triblock copolymer PLD-b-PEG-b-PLD and cationic
DOX via electrostatic interactions. DOX (1 mg/mL) and PLD-b-
PEG-b-PLD (1 mg/mL) were dissolved separately in distilled
water. These two aqueous solutions were then mixed, with
the molar ratio of DOX to carboxylate groups in the micelle
(R ¼ [DOX]/[COOH]) ranging from 0.25 to 0.5 [15]. Unbound
DOXwas removed by ultrafiltration by using Amicon®Ultracel
centrifugal filter devices (molecular weight cut-off, 10,000 Da;
Millipore, Billerica, MA, USA) pretreated with free DOX [4]. The
DOX concentration in the filtrates was determined by
measuring the absorbance at 480.5 nm by using a UV/Vis
spectrophotometer (U-2800, Hitachi, Japan) [4].2.3. UV/Vis and fluorescence studies
A UV/Vis spectrometer was used to conduct a wavelength
scan of the free drug and TBIC micelles. An aqueous solution
of DOX was screened, followed by a scan of DOX-loaded TBIC
micelle solutions over a wavelength range of 200 nme650 nm.
The fluorescent spectra of free DOX and TBICmicelleswere
analyzed using a fluorescence spectrometer (LS 55, Perki-
nElmer, USA). The data were recorded using an excitation
wavelength of 480 nm and a bandwidth of 5 nm for excitation
and emission. All measurements were conducted at room
temperature, and the concentration of DOX was constant in
all the samples.2.4. Drug loading
Drug loading was assessed using UV/Vis spectrophotometry.
Unbound DOX was removed by ultrafiltration, and the
micellar drug concentration was determined by measuring
the absorbance of filtrates at 480.5 nm. Loading capacity (%)
and loading efficiency (%) were calculated as follows:
Loading capacity ð%Þ ¼ ðDOXtotal DOXunboundÞðMicelletotalÞ  100
Loading efficiency ð%Þ ¼ ðDOXtotal DOXunboundÞðDOXtotalÞ  100
where DOXtotal, DOXunbound, and Micelletotal are the total
amount of DOX added, unbound DOX, and micelles
respectively.
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The hydrodynamic particle sizes, polydispersity index (PDI),
and z-potential of the TBIC micelles were measured by dy-
namic light scattering (DLS) using the Zetasizer Nano S90
(Malvern Instruments, Worcestershire, UK) with an He-Ne
laser source, operating at a wavelength of 633 nm with a 90
scattering angle. The hydrodynamic size, PDI, and z-potential
were determined using the Nano DTS software (version 6.34)
provided by the manufacturer. All measurements were per-
formed at room temperature, and mean values were calcu-
lated followingmeasurement of at least three sets of ten runs.
2.6. Morphological analysis
The morphologies of TBIC micelles were observed by trans-
mission electron microscopy (TEM; H-7600, Hitachi, Tokyo,
Japan) at an accelerating voltage of 100 kV. The micelles were
stained with 2% (w/v) phosphotungstic acid, dropped onto
copper grids with films, air-dried under an infrared lamp for
10 min, and observed using TEM.
2.7. In vitro drug release studies
The release profiles of DOX fromTBICmicelleswere studied in
phosphate-buffered saline (PBS, pH 7.4, 0.14 M NaCl) and ac-
etate buffered saline (ABS, pH 5.0, 0.14MNaCl) by dialysis with
a molecular weight cut-off of 3.5 kDa (Spectrum Laboratories,
CA, USA). The experimentswere performed in a shakingwater
bath maintained at 37 C and 100 rpm. At specified time in-
tervals (1e48 h), 5 mL of sample was withdrawn from tubes
containing 30mL releasemedium, and replacedwith an equal
volume of fresh buffer solution. The collected samples were
analyzed using a spectrophotometer to determine the con-
centration of DOX by measuring absorbance at 480.5 nm. The
amount of DOX in the dialysis bag was equal for every sample,
and the experiment was conducted in triplicate under each
condition. The amount of DOX released was expressed as a
percentage of the total DOX and plotted as a function of time.
2.8. In vitro cytotoxicity assay
The in vitro cytotoxicity of free DOX and TBICmicelles in the A-
549 human lung cancer cell line was assessed using the MTT
assay. In brief, 1  104 A-549 cells were seeded in 96-well
plates and allowed to attach for 24 h at 37 C. The cells were
treated with free DOX or TBIC micelles for 24 h at 37 C. To
assess the toxicity of the polymer itself, PLD-b-PEG-b-PLD
aqueous solutions were also incubated with A-549 cells in
separate plates. After treatment for 24 h, the cells were
washed twice with PBS andmaintained in RPMI mediumwith
10% FBS for additional 72 h. The cells were then incubated
with 100 ml of MTT solution (1 mg/mL) for 3 h before adding
DMSO (100 ml) to dissolve the MTT formazan crystals. The
absorbance at 570 nmwasmeasured with amicroplate reader
(Multiskan EX, Thermo Scientific, USA). All measurements
were performed eight times. The cell viability (%) was calcu-
lated using the following equation:
Cell viability ð%Þ ¼ Asample

Acontrol
 100where Asample and Acontrol were the absorbance of the sample
(treated cells) and the control (untreated cells), respectively.
IC50 values (the concentration that caused 50% reduction in
cell viability) were calculated using GraphPad Prism ver. 5.0
(GraphPad Software, San Diego, CA).
2.9. Cellular uptake study
The cellular uptake of TBIC micelles was investigated using
confocal laser scanning microscopy. A-549 cells at 70e80%
confluency were trypsinized and seeded on coverslips in a 12-
well plate at a density of 1.0  105 cells/well. After 24 h, cells
were treated with free DOX or TBIC micelles (5 mg/mL) for
30 min. The cells were then washed three times with PBS
solution before staining with Lysotracker® green DND-26
(100 nM) for 10 min. The cells were again washed twice with
PBS, fixed for 15 min with 4% paraformaldehyde at room
temperature, and rinsed with 4 C PBS solution. Subsequently,
the coverslips were taken out of the wells, carefully mounted
on glass slides with one drop of gel/mount solution (M01,
Biomeda, USA), sealed with nail polish, and observed by
confocal laser scanning microscopy (Nikon A1, Japan).
2.10. In vivo pharmacokinetic studies
2.10.1. Animals
The experimental protocols for the animal studies were
approved by the Institutional Animal Ethical Committee,
Yeungnam University, South Korea. Male SpragueeDawley
rats (250 ± 10 g; 8 weeks) (Orient Bio. Inc., Seungnam, South
Korea) were fasted for 12 h prior to the experiments.
2.10.2. Administration and blood collection
The rats were divided into three groups and anesthetizedwith
diethyl ether. The right femoral artery of each rat was can-
nulated with a polyethylene tube (PE-50, BD, Maryland, USA).
The tube was flushed with 0.3 mL of heparinized normal sa-
line solution (100 IU) to prevent blood clotting. Free DOX so-
lution or TBIC micelle solution was administered
intravenously at a dose of 10 mg/kg as DOX. Blood samples
(250 ml) were collected from the left femoral artery at specified
intervals. The samples were centrifuged at 13,000 rpm for
10 min to obtain a plasma supernatant for further analyses.
2.10.3. Blood sample analysis
Plasma DOX concentration was analyzed by high-
performance liquid chromatography (HPLC) using previously
reported methods, with slight modification [29]. Briefly, 150 ml
of plasma was deproteinized by mixing with 150 ml of meth-
anol, followed by vortexing and mild bath sonication for
5 min. The samples were then centrifuged at 13,000 rpm for
10 min. The supernatant was separated and evaporated in a
centrifugal evaporator (Modul 3180C, Biotron, South Korea).
The residue was reconstituted in 100 ml of methanol and
quantified by HPLC (Hitachi, Japan) with an Inertsil® ODS-3
column (GL Science, 5 mm, 4.6  150 mm). The mobile phase
was composed of methanol/water/acetic acid at a volume
ratio of 50/49/1 (pH 2.9), with a flow rate of 1.0 mL/min. The
UV/Vis detector (Model L-2420) was set at 254 nm. Pharma-
cokinetic parameters such as the area under the drug
Fig. 1 e Schematic illustration of the formation of TBIC micelles.
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rate constant (Kel), and half-life (t1/2) were calculated using
non-compartmental analysis (WinNolin® software; profes-
sional edition, version 2.1; Pharsight Co., CA, USA). Levels of
statistical significance were assessed using analysis of vari-
ance (ANOVA). Differences were considered to be statistically
significant when P < 0.05. All data were expressed as
mean ± standard deviation (SD).Fig. 2 e (A) Average hydrodynamic diameter, (B) PDI, and
(C) z-potential of TBIC micelles at various pH and
compositions (R). R = 0.25, white bar or open circles;
R = 0.50, black bar or filled squares. The data are presented
as mean ± SD (n = 3).3. Results and discussion
3.1. Preparation of TBIC micelles
DOX-loaded TBICmicelles were formed by ionic complexation
between anionic PLD-b-PEG-b-PLD polymers (pKa ¼ 4.0) and
cationic DOX (pKa ¼ 8.3), as shown in Fig. 1. Electrostatic in-
teractions allowedDOX to be immobilized in the cores of these
TBIC micelles [15]. The micelles were formulated at [DOX]/
[COOH] molar ratios (R) ranging from 0.25 to 0.5. Fig. 2 shows
the average particle sizes, PDI, and z-potential of TBICmicelles
(R ¼ 0.25 and 0.5) at various pH. At the lower drug:polymer
ratio of R¼ 0.25 and pH 7, TBICmicelles showedmuch smaller
particle size (~60 nm). However, at R ¼ 0.5, slight increases in
particle size of TBIC micelles were observed at all pH studied.
This is because the increased hydrophobicity in TBIC micelles
with a high R value induced slight aggregation, which can
cause the increased size. Notably, there was no precipitation
of TBIC micelles in aqueous solutions. In all cases, every
mixture had a nanometer-scale size and low PDI of approxi-
mately 0.2. In addition, PEG segments prevented the agglom-
eration of nanoparticles via steric repulsion and decreased
micelle hydrophobicity [15,30]. It is also worth noting that
increased acidity of the mixture was associated with
increased particle hydrodynamic diameter. This was owing to
a reduction in the level of deprotonated forms of the PLD
blocks, and the resulting reduction in the binding force driving
complex formation [5]. The z-potential values of TBICmicelles
are presented in Fig. 2C. At R ¼ 0.25 and 0.5, an increase in the
amount of DOX added to PLD-b-PEO-b-PLD resulted in an in-
crease in z-potential. Compared to R ¼ 0.25, the z-potential of
TBIC micelles at R ¼ 0.5 showed slightly lower negativity. This
was because of the different degree of neutralization by the
increased amount of DOX in the complex.
Fig. 4 e Transmission electron microscopy images of TBIC
micelles. The length of the scale bar was 100 nm at
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physicochemical interactions between DOX and polymers. A
chromophore, composed of three aromatic hydroxyan-
thraquinonic rings in the structure of DOX, was used to clarify
its interactions with other molecules [31]. As depicted in
Fig. 3A, the UV/Vis spectra of free DOX and TBIC micelles
revealed only slight differences in the visible absorption
spectrum. However, the presence of a redshift in the absorp-
tion peaks was clearly indicative of DOXeDOX interactions,
through p-p stacking effects [22,31e33]. Furthermore, the
increased local concentration of DOX in the core of TBIC mi-
celles resulted in decreased absorbance. Fluorescent spectra
provided more information (Fig. 3B), with a significant
decrease in fluorescence intensity observed in the DOX from
TBIC micelles, compared to that in free solution at the same
concentration. This reduction in DOX fluorescence intensity
could be attributed to the location of the DOX molecules,
whichwere bound to the deprotonated COOHgroup in the PLD
chain within the micelle core [15,24]. The quenched DOX
fluorescence therefore indicated that DOX had been success-
fully incorporated into the TBIC micelle core.
TEM images revealed the structural morphology of the
TBICmicelles (Fig. 4), which clearly showed spherical particlesFig. 3 e (A) UV/Vis spectra, and (B) fluorescence emission
spectra of free DOX (d) and TBIC micelles (,,,,,,,).
Concentration of DOX is 50 mg/mL.
10,000  magnification.with coreeshell structure. These showed good particle integ-
rity, suggesting strong interactions between PLD and DOX.
The high contrast cores, which consisted of the hydrophobic
PLD/drug complex, were surrounded by a gray boundary,
indicating the PEG blocks. The narrowly distributed TBIC mi-
celles had particle sizes of less than 100 nm, corresponding
well to the DLS data.3.2. Drug loading and in vitro release study
The loading capacity and efficiency of TBICmicelles at various
molar ratios weremeasured by UV/Vis spectroscopy. The DOX
loading capacities of TBIC micelles were 36.8 ± 1.5 w/w% and
69.4 ± 4.7 w/w% for R ¼ 0.25 and 0.5, respectively. In all com-
plexes, the loading efficiencies of DOXweremaintained above
90%. It is worth noting that the DOX payload in the micelles
was doubled by increasing R from 0.25 to 0.50. This phenom-
enon might indicate that all the additional DOX interacted
with unoccupied carboxylic groups in the polymer, without
exception. Hence, R ¼ 0.50 was selected as the optimized ratio
for further experiments.
The DOX release profiles were investigated by equilibrium
dialysis of the micelles at 37 C at pH 7.4 or pH 5.0 (Fig. 5). At
physiological pH 7.4, TBIC micelles showed a significantly
prolonged release profile up to 48 h, with only ~34% of the
loaded DOX released during the first 10 h. The majority of the
loaded DOX (about 60%) was still immobilized in the core of
TBIC micelles after 48 h [4,31]. In contrast, the release profiles
dramatically changed at the weakly acidic pH 5.0. During the
first 8 h at pH 5.0, almost 80% of DOX was liberated from the
TBIC micelles. This accelerated release of DOX was attribut-
able to the protonation of carboxylic groups in polymer PLD
Fig. 5 e In vitro DOX release profiles from TBIC micelles at
pH 7.4 (C) and pH 5.0 (B). Micelles were prepared at R = 0.5,
and pH 7.0. The loading amount of DOX for each sample is
200 mg. The data are presented as mean ± SD (n = 3).
Fig. 7 e In vitro cytotoxicity of free DOX (black bar), TBIC
micelles (white bar), and free polymer (gray bar) in A-549
cells. TBICmicelles was prepared at R = 0.5, and pH 7.0. The
data are presented as mean ± SD (n = 6). a: P < 0.01
compared to free DOX. b: P < 0.05 compared to free DOX.
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DOX and PLD [4,15,34]. As reported previously, extraordinarily
low pH (pH 5.7e7.2) is a phenotype distinguishing solid tumors
from the surrounding tissues [31,35]. In addition, more acidic
conditions can be found in endosomes (pH 5e6) and lyso-
somes (pH 4e5) [3,35]. Therefore, this pH-sensitive release of
micelles could be triggered when the nanoparticles encounter
acidic environments of cancerous sites or cell organelles.3.3. In vitro cellular uptake and cytotoxicity
Cellular uptake of DOX in the human A-549 cell line was
characterized using confocal laser scanning microscopy. Pre-
vious studies have shown that BIC micelles based on poly-
peptides enter cancer cells via endocytosis, subsequently
moving from endosomes to lysosomes [2,36,37]. Similarly,
TBIC micelles exhibited a high level of co-localization with
lysosomes in A-549 cells within 30min (Fig. 6). In contrast, free
DOX (control) was only detected in the nuclei, and no co-
localization was observed. This phenomenon highlighted
the feasibility of lysosomal pH-triggered DOX release from BICFig. 6 e In vitro cellular uptake studies of TBIC micelles in A-54
30 min at 37 C to TBIC micelles and Lysotracker® (Green) for 1
micelles within the lysosomes.micelles, as well as degradation of the carrier at the cellular
level.
Fig. 7 shows the cytotoxicity of DOX-loaded TBIC micelles
in the A-549 cell line, as observed using the MTT assay. Cell
viability was progressively reduced in a TBIC micelle dose-
dependent manner, although the micelles showed signifi-
cantly less cytotoxicity than that shown by free DOX. The
reduced cytotoxic activity of TBIC micelles resulted from the
more sustained release of DOX from these micelles. Impor-
tantly, polymer (PLD-b-PEG-b-PLD) did not have any influence
on cell viability over the entire range of concentrations used
for the treatment. These results suggested that tri-block
copolymer was biocompatible.3.4. Pharmacokinetic study
The plasma concentration-time profiles of DOX after intra-
venous injection of DOX solution and DOX-loaded TBIC mi-
celles at a dose of 10 mg/kg to rats are shown in Fig. 8 and the
relevant pharmacokinetic parameters are listed in Table 1.
Administration of TBIC micelles produced a markedly higher
DOX concentration than did free DOX administration, which9 human lung cancer cells. A-549 cells were exposed for
0 min. Images show significant co-localization of TBIC
Fig. 8 e In vivo pharmacokinetic profiles after intravenous
administration of free DOX (,) and TBIC micelles (C) in
rats at a dose of 10 mg/kg. TBIC micelles were prepared at
R = 0.5, and pH 7.0. The data are presented as mean ± SD
(n = 3).
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istration. Compared to the free DOX solution, DOX delivery
using TBIC micelles resulted in a 7-fold increase in t1/2 and
AUCall, and a 7-fold decrease in clearance. These in vivo
pharmacokinetic characteristics of DOX from the TBIC mi-
celles were understood to be related to the longevity of the
nanoparticles in the circulation.
The major advantages of polymeric micelles as circulating
drug carriers are that non-specific interactions with healthy
tissues and premature clearance by RES are hindered by steric
repulsion by the hydrophilic palisades, generally PEG, sur-
rounding the core [5,38]. Thus, these characteristics suggested
that this system possessed the potential to provide a feasible
anti-cancer drug delivery system that might lead to improved
biological performance in vivo.4. Conclusions
In summary, TBIC micelles were prepared by polyion
complexation of an anionic triblock copolymer, PLD-b-PEG-b-Table 1 e Pharmacokinetic parameters of DOX after
intravenous administration of free DOX or TBIC micelles
in rats (10 mg/kg).
Free DOX TBIC micelles
Cmax (㎍/mL) 6.54 ± 1.36 11.80 ± 2.28
a
Kel (h
1) 0.97 ± 0.47 0.11 ± 0.03a
t1/2 (h) 0.82 ± 0.32 6.46 ± 1.33
b
AUCall (㎍ min/mL) 7.21 ± 1.14 48.94 ± 2.53
b
MRT (min) 1.64 ± 0.67 10.45 ± 2.66b
Data are presented as the mean ± SD (n ¼ 3).
a P < 0.05 compared to the free DOX group.
b P < 0.01 compared to the free DOX group.PLD, and a cationic drug, DOX, via electrostatic interactions.
These micelles showed a narrow size distribution and incor-
porated a substantial amount of active drug in a reasonably
stable manner. Moreover, they exhibited a pH-responsive
release pattern that could facilitate delivery of a higher con-
centration of the drug to solid tumors. DOX-loaded TBIC mi-
celles were significantly less cytotoxic to A-549 cells than free
DOX, which was consistent with the sustained release of DOX
from the carriers. Furthermore, DOX-loaded TBIC micelles
were internalized into A-549 cells and they showed co-
localization with Lysotracker® Green, which suggested that
they reached late endosomes or lysosomes. Reduced clear-
ance of micelle-delivered DOX from the circulation was
observed in vivo. Based on these findings, it might be
concluded that TBIC micelles comprising PLD-b-PEG-b-PLD
showed excellent drug-delivery properties.Acknowledgment
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